Gout & Hyperuricemia Drug Pipeline — PatSnap Eureka
Gout & Hyperuricemia Drug Pipeline: Uricase, XO Inhibitor & URAT1 Inhibitor Approaches
Patent and literature intelligence across three mechanistically distinct urate-lowering modalities — from pegylated uricase biologics to next-generation URAT1 inhibitors and dual-mechanism XOR compounds.
The Molecular Architecture of Gout and Hyperuricemia
Hyperuricemia is defined as a biochemical state in which blood uric acid exceeds 7.0 mg/dL in men or 6.0 mg/dL in women, precipitating monosodium urate crystal deposition in joints, tendons, renal parenchyma, and soft tissues. Gout — manifesting as acute gouty arthritis, tophaceous gout, gouty nephropathy, and urolithiasis — is the principal clinical consequence.
The molecular targets driving the pipeline span the full purine catabolism pathway. PatSnap's life sciences intelligence platform maps these across thousands of patent families globally. Xanthine oxidoreductase (XOR/XO) catalyzes the final two steps of purine degradation — hypoxanthine → xanthine → uric acid — and is inhibited by allopurinol and febuxostat-class compounds. Multiple Takeda Pharmaceuticals filings explicitly reference XOR inhibition as the mechanistic basis for joint protection and renal preservation.
URAT1 (SLC22A12), the renal proximal tubule urate transporter responsible for the majority of urate reabsorption, is the single most frequently addressed transporter target across retrieved patents. Filings from Japan Tobacco Inc., Teijin Pharma, J-Pharma, Sunshine Lake Pharma, Ardea Biosciences, and Arthrosi Therapeutics all target URAT1 inhibition. University of Tokyo and Nariyoshi Shinomiya patents also identify URAT1 in combination with GLUT9 (SLC2A9) and NPT1/NPT4 transporters as part of the urate excretion network.
ABCG2 (ATP-binding cassette subfamily G member 2) is an intestinal/renal urate exporter whose Q141K variant (rs2231142) is associated with both elevated serum urate and a disproportionately elevated risk of progressing from hyperuricemia to gout (OR = 1.85 in Europeans and Polynesians), suggesting a role beyond urate elevation alone, per academic literature from the University of Otago and Radboud University Medical Center.
Three Mechanistically Distinct Urate-Lowering Strategies
Patent intelligence from PatSnap Eureka reveals a pipeline spanning biologic urate degradation, enzymatic synthesis inhibition, and transporter blockade — with active combination strategies across all three.
Pegylated Uricase (Urate Degradation)
Uricase enzymes catalyze oxidation of uric acid to allantoin, bypassing the metabolic block present in humans. PEGylation extends half-life and reduces immunogenicity. The central challenge — anti-drug antibody (ADA) formation leading to treatment failure and infusion reactions — is the dominant engineering problem addressed across multiple Selecta Biosciences and Horizon Therapeutics patent families. Selecta pairs pegsiticase with rapamycin-loaded synthetic nanocarriers (SVP-Rapamycin) to induce antigen-specific immune tolerance. Horizon addresses ADA via co-administration with methotrexate or azathioprine.
Most IP-active 2024–2025XOR Inhibitors (Uric Acid Synthesis Blockade)
XOR inhibition reduces de novo uric acid synthesis. Takeda Pharmaceuticals' large portfolio deploys XOR inhibitors across three clinical applications: prevention of gout flares (with NSAIDs, six-month protocols), joint damage stabilization, and renal function preservation. LG Chem's active 2023–2024 filings on 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid specify 50–200 mg/day orally for 12 weeks in patients with sUA 8–12 mg/dL, targeting reduction to <6.0 mg/dL in ≥55% of patients — the most granular clinical dosing claim in this dataset. Sunshine Lake Pharma also filed dual XO + URAT1 inhibitory compounds.
LG Chem: Phase II/III signalsURAT1 Inhibitors (Uricosuric Agents)
URAT1 inhibitors enhance renal urate excretion by blocking the SLC22A12 transporter in the renal proximal tubule. This is the most chemically diverse modality in the dataset, with multiple structural classes: pyridines (Teijin Pharma), triazoles and naphthalene-cyanopyridine series (Ardea Biosciences / lesinurad-related), indoles and fused heterocycles (J-Pharma), and nitrogen-containing condensed rings (Japan Tobacco). Arthrosi Therapeutics explicitly targets reduced CYP2C9 metabolic liability as a safety-differentiation strategy relative to benzbromarone (known for hepatotoxicity via CYP2C9). Cymabay Therapeutics specifically targets patients with impaired renal function.
Highest assignee diversityAlternative & Adjunct Urate-Lowering Agents
Smaller modality clusters include diacerein/rhein anthraquinone compounds (TWI Biotechnology) for hyperuricemia and associated metabolic disorders including type 2 diabetes and metabolic syndrome. Kissei Pharmaceutical filed SNT2 inhibitors and 8-modified purine nucleoside derivatives. An observational database study (Sheu, 2020) analyzing approximately 300,000 adults with type 2 diabetes reported lower gout risk in SGLT2 inhibitor users vs. GLP-1 receptor agonist users, signaling an emerging urate-lowering role for dapagliflozin-class agents. AstraZeneca's triple combination — verinurad + XO inhibitor + dapagliflozin — directly exploits this signal for cardiorenal positioning.
SGLT2 inhibitors: emerging signalKey Quantitative Signals from the Gout & Hyperuricemia Patent Dataset
Data points extracted from patent filings and academic literature via PatSnap Eureka. All values are sourced directly from retrieved records.
LG Chem XOR Inhibitor: Clinical Dosing Benchmark
Dose range (50–200 mg/day, 12 weeks) and target response rate (≥55% achieving sUA <6.0 mg/dL) from Peru patent filing — most granular clinical claim in this dataset.
ABCG2 Q141K Variant: Gout Progression Risk (OR = 1.85)
Academic evidence (University of Otago, Radboud University) shows ABCG2 Q141K (rs2231142) independently elevates gout progression risk beyond serum urate elevation in Europeans and Polynesians.
Key Patent Filing Timeline by Assignee
Filing date ranges across major assignees, illustrating portfolio maturity — from Takeda's established XOR IP (2007–2017) to LG Chem's active 2023–2024 filings and Selecta's 2017–2024 uricase platform.
Key Pipeline Assignees, Modalities & Apparent Development Stage
Derived from patent filing language and clinical signal analysis via PatSnap analytics. Stages are inferred from patent content — not from regulatory submissions.
Need freedom-to-operate analysis across these assignees?
PatSnap Eureka maps overlapping IP territories across all three gout modalities — including the ADA-mitigation space.
Combination Approaches & Strategic Implications
Patent intelligence from PatSnap Eureka reveals a clear shift from single-agent paradigms toward multi-modal combination strategies, particularly for patients with concurrent CKD, heart failure, or metabolic syndrome.
Pegylated Uricase + Immunosuppressant
Both Selecta Biosciences (nanocarrier-encapsulated rapamycin) and Horizon Therapeutics (systemic MTX or azathioprine) pursue independent but mechanistically complementary strategies to overcome the ADA barrier to sustained pegloticase therapy. This is the most IP-active area in the uricase sub-field, with active filings as recent as 2024–2025. Drug developers and IP strategists should monitor freedom-to-operate in the ADA-mitigation space.
URAT1 + XOR Dual-Mechanism Compounds
Sunshine Lake Pharma (WO 2017) and AstraZeneca (verinurad + XO inhibitor) both represent patented dual-mechanism strategies. AstraZeneca extends this to a triple combination: verinurad (URAT1) + XO inhibitor + dapagliflozin (SGLT2), addressing hyperuricemia in the context of chronic kidney disease and heart failure — a cardiorenal metabolic syndrome positioning. This signals a shift toward fixed-dose combination (FDC) products.
What the Evidence Base Reveals About Pipeline Maturity
The Selecta Biosciences pegylated uricase + SVP-Rapamycin (SEL-212) program represents the clearest clinical-stage evidence in the dataset. The IL jurisdiction filing references Phase Ia clinical trial data — specifically mean serum uric acid levels across five cohorts following a single intravenous infusion — and ADA measurements in non-human primates.
Horizon Therapeutics pegloticase + MTX filings (US, CA, EP, WO, BR) reference patients with tophaceous gout, refractory gout, and chronic gouty arthropathy as the target population. The claimed infusion protocol optimization (<120 min, <250 mL) implies procedural improvements derived from prior clinical experience. Per FDA context, pegloticase (KRYSTEXXA) is an approved biologic.
A randomized, double-blind, positive-controlled clinical study from Nizam's Institute of Medical Sciences (published 2020, n=59) in CKD patients with hyperuricemia used febuxostat 40 mg/day as the active comparator, confirming its use in renally impaired populations. An observational database analysis (Sheu, 2020) in approximately 300,000 adults with type 2 diabetes showed lower gout incidence with SGLT2 inhibitors vs. GLP-1 agonists — observational evidence only, not from an interventional trial for gout.
No retrieved results contain Phase III trial outcomes, regulatory submission data, or approved product labeling for any novel compound in the pipeline. PatSnap's IP analytics platform enables continuous monitoring of new filings as these programs advance. For URAT1 inhibitor chemical design, EBI ChEMBL provides complementary bioactivity data.
Gout & Hyperuricemia Drug Pipeline — key questions answered
Three mechanistically distinct therapeutic approaches define the current and pipeline pharmacological landscape: uricase-based urate degradation, xanthine oxidase/oxidoreductase (XO/XOR) inhibition of uric acid biosynthesis, and URAT1-mediated blockade of renal urate reabsorption.
The central immunological challenge — anti-drug antibody (ADA) formation leading to treatment failure and infusion reactions — is the dominant engineering problem addressed across multiple Selecta Biosciences and Horizon Therapeutics patent families.
The Peru filing specifies a patient population (sUA 8–12 mg/dL), dose range (50–200 mg/day), duration (12 weeks), and response benchmark (≥ 55% achieving sUA < 6.0 mg/dL) — language characteristic of a Phase II/III clinical protocol. This is the most granular clinical dosing claim for a novel XOR inhibitor in this dataset.
Academic literature retrieved from the University of Otago and Radboud University Medical Center demonstrates that the ABCG2 Q141K variant (rs2231142) is associated with both elevated serum urate and a disproportionately elevated risk of progressing from hyperuricemia to gout (OR = 1.85 in Europeans and Polynesians), suggesting a role beyond urate elevation alone.
AstraZeneca's verinurad + XO inhibitor + dapagliflozin filings, Sunshine Lake Pharma's dual-target compounds (WO 2017), and Japan Tobacco's multi-class combination patents all signal that single-agent paradigms are giving way to combination positioning, particularly for patients with concurrent CKD, heart failure, or metabolic syndrome.
Arthrosi Therapeutics, Inc. (SG 2019) developed URAT1-targeting compounds designed with reduced CYP2C9 metabolic liability — an explicit safety-differentiation strategy relative to benzbromarone (known for hepatotoxicity via CYP2C9).
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About the Gout PipelineAccelerate Your Gout & Hyperuricemia Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Monitor URAT1, XOR, and uricase pipeline filings in real time.
References
- URAT1 inhibitor — J-Pharma Co., Ltd., 2021, ES [Patent]
- Carboxyl-substituted (hetero)aromatic ring derivatives — Sunshine Lake Pharma Co., Ltd., 2021, ES [Patent]
- Carboxy substituted (hetero) aromatic ring derivatives — Sunshine Lake Pharma Co., Ltd., 2017, WO [Patent]
- Methods for stabilizing joint damage using xanthine oxidoreductase inhibitors — Gunawardhana/Takeda, 2011, WO [Patent]
- Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors — Takeda Pharmaceuticals North America, Inc., 2010, WO [Patent]
- Methods for preventing or reducing gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents — Taneja/Takeda, 2008, WO [Patent]
- Pharmaceutical composition includes 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid — LG Chem, Ltd., 2024, PE [Patent]
- Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid — LG Chem, Ltd., 2024, BR [Patent]
- Methods of treating gout — Horizon Therapeutics Ireland DAC, 2022, WO [Patent]
- Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect — Horizon Pharma Rheumatology LLC, 2020, WO [Patent]
- Novel compounds and compositions and methods of use — Ardea Biosciences Inc., 2012, AU [Patent]
- Pyridine derivative — Teijin Pharma Limited, 2018, ES [Patent]
- University of Otago — ABCG2 Q141K genetic association study (2020) [Academic Literature]
- Nizam's Institute of Medical Sciences — Febuxostat vs. Terminalia bellerica in CKD hyperuricemia (RCT, n=59, 2020) [Clinical Paper]
- Sheu W. — SGLT2 inhibitor gout risk reduction vs. GLP-1 agonists (~300,000 adults, 2020) [Observational Paper]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within a targeted patent and literature dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.